A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
NCT ID: NCT05034952
Last Updated: 2024-12-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
303 participants
INTERVENTIONAL
2021-08-30
2021-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Participants received placebo matched to VX-548 and Hydrocodone bitartrate/ acetaminophen (HB/APAP) for 2 days.
Placebo (matched to VX-548)
Placebo matched to VX-548 for oral administration.
Placebo (matched to HB/APAP)
Placebo matched to HB/APAP for oral administration.
HB/APAP
Participants received HB 5 mg / APAP 325 milligrams (mg) every 6 hours (q6h) for 2 days.
HB/APAP
Capsules for oral administration.
VX-548: Low Dose
Participants received VX-548 60 mg as first dose, followed by VX-548 30 mg every 12 hours (q12h) for 2 days.
VX-548
Tablets for oral administration.
VX-548: High Dose
Participants received VX-548 100 mg as first dose, followed by VX-548 50 mg q12h for 2 days.
VX-548
Tablets for oral administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VX-548
Tablets for oral administration.
HB/APAP
Capsules for oral administration.
Placebo (matched to VX-548)
Placebo matched to VX-548 for oral administration.
Placebo (matched to HB/APAP)
Placebo matched to HB/APAP for oral administration.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant scheduled to undergo an abdominoplasty without collateral procedures
* After Surgery:
* Participant is lucid and able to follow commands
* All analgesic guidelines were followed during and after the abdominoplasty
* Abdominoplasty procedure duration \<=3 hours without collateral procedures (for example., liposuction)
Exclusion Criteria
* Prior history of abdominoplasty, intra-abdominal and/or pelvic surgery
* History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
* Any prior surgery within 1 month before the first study drug
* After Surgery:
* Participant had medical complications during the abdominoplasty that, in the opinion of the investigator, should preclude randomization
* Participant had collateral procedures during the abdominoplasty
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Research Center
Phoenix, Arizona, United States
Lotus Clinical Research
Pasadena, California, United States
Chesapeake Research Group
Pasadena, Maryland, United States
Midwest Clinical Research Center
Dayton, Ohio, United States
First Surgical Hospital
Bellaire, Texas, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
JBR Clinical Research
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF; VX21-548-101 and VX21-548-102 Trial Groups. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405. doi: 10.1056/NEJMoa2209870.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VX21-548-102
Identifier Type: -
Identifier Source: org_study_id